Mikrobiomik key facts
- Operator of a biopharmaceutical company intended to research, develop, produce, and market biological drugs based on the human microbiome.
- Mikrobiomik’s last known valuation is $16.7M.
- It has raised $10.3M; the latest was Equity Crowdfunding ($710K) in Sep 2025.
- Notable investors include Seed Capital Bizkaia, Basque Government, San Ignacio SL, Ekintzaile, Government of Spain — 8 tracked in total.
- Status: Privately Held (backing).
- ·Watch Mikrobiomik: the Monday email on marks, rounds and moves
Mikrobiomik funding rounds
No funding rounds for Mikrobiomik are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Mikrobiomik valuation
Mikrobiomik's last known valuation is $16.7 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Mikrobiomik investors
8 investors are on record for Mikrobiomik, including Seed Capital Bizkaia, Basque Government, San Ignacio SL and Ekintzaile.
About Mikrobiomik
Operator of a biopharmaceutical company intended to research, develop, produce, and market biological drugs based on the human microbiome. The company's biological medicine treats both the primary episode and recurrence of Clostridium difficile infection with the administration of 4 capsules with full-spectrum and purified intestinal microbiota technology as a single dose, enabling patients to receive treatments based on human microbiota.
- Sector
- Healthcare
- HQ
- Bilbao, Spain
- Founded
- 2018
- Employees
- 21
- Website
- mikrobiomik.net/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Mikrobiomik’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.